Clinical trials
Phase 3 Lymphoma, B-Cell, Marginal Zone trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2003 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 5 |
| Terminated | 5 |
| Active, not recruiting | 2 |
| Recruiting | 2 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 4 |
| Gilead Sciences | 2 |
| BeOne Medicines | 1 |
| French Study Group on Chronic Lymphoid Leukemia | 1 |
| Incyte Corporation | 1 |
| International Extranodal Lymphoma Study Group (IELSG) | 1 |
| Janssen Research & Development, LLC | 1 |
| Lymphoma Study Association | 1 |
| MEI Pharma, Inc. | 1 |
| Pentixapharm AG | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, B-Cell, Marginal Zone | 16 |
| Lymphoma, Follicular | 12 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 7 |
| Waldenstrom Macroglobulinemia | 6 |
| Lymphoma | 5 |
| Lymphoma, Non-Hodgkin | 5 |
| Burkitt Lymphoma | 4 |
| Lymphoma, Large B-Cell, Diffuse | 4 |
| Lymphoma, Large-Cell, Immunoblastic | 4 |
| Lymphoma, Mantle-Cell | 4 |
Trials
Showing 1 to 16 of 16. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.